Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban.

Authors :: Hiramatsu S
Osanai H
Sakai Y
Sogo Y
Tanaka Y
Matsumoto H
Miyamoto S
Tagahara K
Arai K
Watanabe T
Sakamoto Y
Sakaguchi T
Oguchi S
Kanbara T
Nakashima Y
Asano H
Ajioka M
Source :: Journal of arrhythmia [J Arrhythm] 2024 Aug 27; Vol. 40 (5), pp. 1126-1130. Date of Electronic Publication: 2024 Aug 27 (Print Publication: 2024).
Publication Year :: 2024
Abstract: Background: The distribution of anti-factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated.<br />Methods and Results: The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; p < 0.0001).<br />Conclusions: Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.<br />Competing Interests: The authors declare that there are no conflicts of interest.<br /> (© 2024 The Author(s). Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society.)

Full Text Access

Tools